Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Are anti-vitamin K drugs contraindicated with cetuximab during head-and-neck cancer concomitant radiotherapy?

Brohée D, Henry AR, Castadot P.

Acta Clin Belg. 2013 May-Jun;68(3):237-9.

PMID:
24156231
2.

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK.

N Engl J Med. 2006 Feb 9;354(6):567-78.

3.

Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer.

Yokota T, Onoe T, Ogawa H, Hamauchi S, Iida Y, Kamijo T, Suda T, Yurikusa T, Nishimura T, Yasui H, Onitsuka T.

Jpn J Clin Oncol. 2015 Feb;45(2):183-8. doi: 10.1093/jjco/hyu196. Epub 2014 Nov 23.

4.

Cetuximab and radiotherapy for head and neck cancer.

Posner MR, Wirth LJ.

N Engl J Med. 2006 Feb 9;354(6):634-6. No abstract available.

PMID:
16467552
5.

Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC).

Fury MG, Sherman EJ, Rao SS, Wolden S, Smith-Marrone S, Mueller B, Ng KK, Dutta PR, Gelblum DY, Lee JL, Shen R, Kurz S, Katabi N, Haque S, Lee NY, Pfister DG.

Ann Oncol. 2014 Mar;25(3):689-94. doi: 10.1093/annonc/mdt579. Epub 2014 Feb 3.

6.

Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck.

Okano S, Yoshino T, Fujii M, Onozawa Y, Kodaira T, Fujii H, Akimoto T, Ishikura S, Oguchi M, Zenda S, de Blas B, Tahara M, Beier F.

Jpn J Clin Oncol. 2013 May;43(5):476-82. doi: 10.1093/jjco/hyt030. Epub 2013 Mar 10.

7.

Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer.

Chan A, Teoh D, Sanghera P, Hartley A.

Radiother Oncol. 2009 Dec;93(3):654. doi: 10.1016/j.radonc.2009.05.005. Epub 2009 Jun 11. No abstract available.

PMID:
19524312
8.

Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer.

Teoh DC, Rodger S, Say J, Hartley A.

Clin Oncol (R Coll Radiol). 2008 Nov;20(9):717. doi: 10.1016/j.clon.2008.07.003. Epub 2008 Aug 30. No abstract available.

PMID:
18757187
9.

Manageable early toxicity of cetuximab concurrent with radical radiotherapy for locally advanced head and neck cancer.

Wieczorek A, Hamid A, O'Toole L.

Clin Oncol (R Coll Radiol). 2011 Sep;23(7):496. doi: 10.1016/j.clon.2011.03.004. Epub 2011 Apr 11. No abstract available.

PMID:
21482459
10.

Cost effectiveness of cetuximab concurrent with radiotherapy for patients with locally advanced head and neck cancer in Taiwan: a decision-tree analysis.

Chan AL, Leung HW, Huang SF.

Clin Drug Investig. 2011 Oct 1;31(10):717-26. doi: 10.2165/11588980-000000000-00000.

PMID:
21744880
11.

Cetuximab plus radiotherapy for head and neck cancer.

Hartig F, Pechlaner C.

N Engl J Med. 2006 May 18;354(20):2187; author reply 2187. No abstract available.

PMID:
16710909
12.

Cetuximab plus radiotherapy for head and neck cancer.

Armstrong JG.

N Engl J Med. 2006 May 18;354(20):2187; author reply 2187. No abstract available.

PMID:
16710907
13.

Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.

Argiris A, Duffy AG, Kummar S, Simone NL, Arai Y, Kim SW, Rudy SF, Kannabiran VR, Yang X, Jang M, Chen Z, Suksta N, Cooley-Zgela T, Ramanand SG, Ahsan A, Nyati MK, Wright JJ, Van Waes C.

Clin Cancer Res. 2011 Sep 1;17(17):5755-64. doi: 10.1158/1078-0432.CCR-11-0861. Epub 2011 Jul 12.

14.

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK.

Lancet Oncol. 2010 Jan;11(1):21-8. doi: 10.1016/S1470-2045(09)70311-0. Epub 2009 Nov 10. Erratum in: Lancet Oncol. 2010 Jan;11(1):14.

PMID:
19897418
15.
16.

Cetuximab plus radiotherapy for head and neck cancer.

Cengiz M, Yildiz F, Genc M.

N Engl J Med. 2006 May 18;354(20):2187; author reply 2187. No abstract available.

PMID:
16710908
17.

More on cetuximab in head and neck cancer.

Mell LK, Weichselbaum RR.

N Engl J Med. 2007 Nov 22;357(21):2201-2; author reply 2202-3. No abstract available.

18.
19.

Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab.

Ye AY, Hay JH, Laskin JJ, Wu JS, Ho CC.

J Cancer Res Ther. 2013 Oct-Dec;9(4):607-12. doi: 10.4103/0973-1482.126455.

20.

[Short-term efficacy of cetuximab combined with radiotherapy or chemotherapy on head and neck cancer: a report of 11 cases].

Xia LP, Zhang B, Liu MZ, Hu PL, Chen XX, Guo GF, Qiu HJ, Rong YM, Qian SY, Zhou FF, Huang YY, Wang TL.

Ai Zheng. 2009 Sep;28(9):977-82. Chinese.

PMID:
19728918
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk